ICIs, encompassing inhibitors targeting PD‐1, PD‐L1, and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), have demonstrated unprecedented efficacy in treating numerous cancers.19 This evidence concerns the gene PDCD1 and cancer.